Literature DB >> 15797947

U.S. spending for mental health and substance abuse treatment, 1991-2001.

Tami L Mark1, Rosanna M Coffey, Rita Vandivort-Warren, Hendrick J Harwood, Edward C King.   

Abstract

Spending for mental health and substance abuse (MHSA) treatment in the United States totaled dollar 104 billion in 2001, representing 7.6 percent of all health care spending. The nominal MHSA annual spending growth rate from 1991 to 2001 was 5.6 percent, almost one percentage point below the growth rate for all health care (6.5 percent). During this period, Medicaid has increased to be the largest payer of mental health care, with prescription drugs the fastest-growing spending component. Private insurance payment for substance abuse actually dropped in real dollars, increasing the public share of substance abuse spending.

Mesh:

Year:  2005        PMID: 15797947     DOI: 10.1377/hlthaff.w5.133

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  19 in total

1.  Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia.

Authors:  James Walkup; Ayse Akincigil; Donald R Hoover; Michele J Siegel; Shahla Amin; Stephen Crystal
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

Review 2.  Mental health policy and psychotropic drugs.

Authors:  Richard G Frank; Rena M Conti; Howard H Goldman
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

3.  Equity in private insurance coverage for substance abuse: a perspective on parity.

Authors:  Colleen L Barry; Jody L Sindelar
Journal:  Health Aff (Millwood)       Date:  2007-10-23       Impact factor: 6.301

4.  Comparing credentialing requirements of substance abuse treatment staff by funding source.

Authors:  Sheryl Pimlott Kubiak; Cynthia L Arfken
Journal:  J Subst Abuse Treat       Date:  2007-10-10

5.  Changes in how health plans provide behavioral health services.

Authors:  Constance M Horgan; Deborah W Garnick; Elizabeth Levy Merrick; Dominic Hodgkin
Journal:  J Behav Health Serv Res       Date:  2007-09-14       Impact factor: 1.505

Review 6.  Rethinking antipsychotic formulary policy.

Authors:  R A Rosenheck; D L Leslie; Susan Busch; Ethan S Rofman; Michael Sernyak
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

7.  Who are the new users of antipsychotic medications?

Authors:  Marisa Elena Domino; Marvin S Swartz
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

8.  Trends in alcohol services utilization from 1991-1992 to 2001-2002: ethnic group differences in the U.S. population.

Authors:  Karen G Chartier; Raul Caetano
Journal:  Alcohol Clin Exp Res       Date:  2011-05-16       Impact factor: 3.455

9.  Geography and the Medicaid mental health care infrastructure: implications for health care reform.

Authors:  Janet R Cummings; Hefei Wen; Michelle Ko; Benjamin G Druss
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

10.  Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.

Authors:  Stan L Banks; Raghotham R Pinninti; Harvinder S Gill; Peter A Crooks; Mark R Prausnitz; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.